Galil Medical has announced the launch of its latest product offerings, the Icepearl 2.1 CX and Iceforce 2.1 CX cryoablation needles. A press release from the company states that the patented needle design characteristics of these new needles offer the largest iceball via the narrowest needle shaft diameter on the market today.
Icepearl 2.1 CX and Iceforce 2.1 CX feature Galil’s proprietary “CX” capabilities, which allow for helium-free active thaw (I-thaw or Fastthaw), along with a track ablation option to address physicians’ concerns regarding track seeding. The “CX” track ablation feature is also available on other Galil cryoablation needles.
Available in both straight and 90°configurations, these new products will be well suited for use in a multitude of clinical settings. Given the increasing scrutiny in today’s healthcare environment, the fact that these needles do not require the use of costly and scarce helium will appeal to hospitals from both an economic and environmental perspective. In addition, Icepearl 2.1 CX and Iceforce 2.1 CX consume significantly less argon gas than other needles and probes currently available in the market.
The company expects that the new cryoablation needles will allow Galil Medical to continue to generate strong revenue growth and deliver on its commitment of achieving positive EBITDA (a measurement of a company’s operating profitability) and positive cash-flow within 18 months, the release adds.
